We look at 19 stocks primed to deliver major events in their career By the Shares team Investors are spoiled for choice when it comes to small cap stocks with
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first LIGHT system, as per the
Widecells Group’s João Andrade discusses the recent Board changes, their new scientific advisory board, WG Partners and what to look forward to in 2018 in this exclusive interview with DirectorsTalk
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of
Widecells Group Plc (LON:WDC) CEO João Andrade talks to DirectorsTalk about the strengthening of its management and advisory team through the appointment of three new board members, the creation of
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that the Company has validated its EarlyCDT®-Liver test on schedule
Microsaic Systems plc (LON:MSYS), the developer of chip-based mass spectrometry (“MS”) instruments designed to improve the efficiency of pharmaceutical R&D, is pleased to announce the appointment of Peter Grant MA
ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are
OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement
Microsaic Systems plc (LON:MSYS) CEO Glenn Tracey joins DirectorsTalk to discuss the signing of a research agreement with a global partner in biopharma. Glenn provides us with some background to
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
